Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy (PROPER)
Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy
About this trial
This is an interventional treatment trial for Proliferative Diabetic Retinopathy focused on measuring Proliferative diabetic retinopathy, anti-vascular endothelial growth factor, optical coherence tomography angiography, macular perfusion, pan-retinal photocoagulation, fluorescein angiography, visual field
Eligibility Criteria
Inclusion Criteria:
- Patients ≥ 18 years old
- Type 1 or 2 diabetes mellitus
- PDR
- Central macular thickness less than 300 µm
Exclusion Criteria:
- Central macular thickness more than 300 µm
- Previous retinal laser treatment
- Ocular conditions that may affect macular perfusion (e.g. retinal vein occlusion, uveitis, vasculitis etc.)
- Any previous treatment for diabetic macular edema.
- Presence of epiretinal membrane involving the macula or vitreomacular traction
- Media opacity such vitreous hemorrhage and dense cataract.
- Patients with previous cataract surgery within the last 3 months.
- Uncontrolled glaucoma
- Thromboembolic events within 6 months
- Tractional retinal detachment.
Sites / Locations
- Faculty of Medicine, Cairo University
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
Anti-vascular endothelial growth factor agent
Targeted retinal photocoagulation
Standard pan-retinal photocoagulation
Intravitreal injections of 1.25 mg/0.05 ml of Bevacizumab every 4 weeks through 12- week visit then pro re nata to complete 12 months according to Protocol S.
Targeted retinal photocoagulation guided by fundus fluorescein angiography will be administered after topical anesthesia, directed to areas of nonperfused peripheral retina plus a 1-disc area margin using the Mainster lens. Subsequent treatments if needed will be delivered at 3 monthly intervals for a minimum follow-up of 12 months. The extent of the laser applied will be determined based on areas of nonperfusion identified by fundus fluorescein angiography.
Standard pan-retinal photocoagulation will be performed at baseline and then every 3 months thereafter if needed, for a minimum follow-up period of 12 months. PRP will be performed at two consecutive sessions with adherence to the guidelines of the Early Treatment Diabetic Retinopathy Study Group. Following topical anesthesia, 1000 to 1200 laser spots will be applied to the retina at each session with a 532 nm frequency doubled Nd-YAG laser (VISULAS, Carl Zeiss, Germany) using a spot size of 300-500 μm. PRP will be applied in all 4 retina quadrants. The Mainster lens will be used. Retreatment will be done according to the Diabetic Retinopathy Clinical Research network protocol S classification for patients with stable, worsening, or with failure of regression of neovascularization.